- Home
- NMIH vs TARS Comparison
NMIH vs TARS Comparison
Compare NMIH & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMIH | TARS |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NMIH | TARS |
|---|---|---|
| Price | $41.92 | $56.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $43.25 | ★ $89.00 |
| AVG Volume (30 Days) | 591.0K | ★ 1.2M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.06 | ★ 48.21 |
| EPS | ★ 1.28 | N/A |
| Revenue | ★ $706,440,000.00 | $451,360,000.00 |
| Revenue This Year | N/A | $56.43 |
| Revenue Next Year | $4.34 | $30.19 |
| P/E Ratio | $32.70 | ★ N/A |
| Revenue Growth | 8.52 | ★ 146.71 |
| 52 Week Low | $34.84 | $38.51 |
| 52 Week High | $43.36 | $85.25 |
Technical Indicators
Market Signals| Indicator | NMIH | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 61.33 | 41.35 |
| Support Level | $36.61 | N/A |
| Resistance Level | $42.15 | $67.14 |
| Average True Range (ATR) | 0.93 | 4.36 |
| MACD | 0.03 | -0.81 |
| Stochastic Oscillator | 54.05 | 14.21 |
Price Performance
Historical ComparisonAbout NMIH NMI Holdings Inc.
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.